{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:19:47Z","timestamp":1791807587281,"version":"4.3.4"},"reference-count":105,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":227,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cirrhosis with complications of liver decompensation and hepatocellular carcinoma (HCC) constitute a leading cause of morbidity and mortality worldwide. Portal hypertension is central to the progression of liver disease and decompensation. The most recent Baveno VII guidance included revision of the nomenclature for chronic liver disease, termed compensated advanced chronic liver disease, and leveraged the use of liver stiffness measurement to categorize the degree of portal hypertension. Additionally, non-selective beta blockers, especially carvedilol, can improve portal hypertension and may even have a survival benefit. Procedural techniques with interventional radiology have become more advanced in the management of refractory ascites and variceal bleeding, leading to improved prognosis in patients with decompensated liver disease. While lactulose and rifaximin are the preferred treatments for hepatic encephalopathy, many alternative treatment options may be used in refractory cases and even procedural interventions such as shunt embolization may be of benefit. The approval of terlipressin for the treatment of hepatorenal syndrome (HRS) in the USA has improved the way in which HRS is managed and will be discussed in detail. Malnutrition, frailty, and sarcopenia lead to poorer outcomes in patients with decompensated liver disease and should be addressed in this patient population. Palliative care interventions can lead to improved quality of life and clinical outcomes. Lastly, the investigation of systemic therapies, in particular immunotherapy, has revolutionized the management of HCC. These topics will be discussed in detail in this review.<\/jats:p>","DOI":"10.1093\/gastro\/goae072","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T17:33:03Z","timestamp":1722879183000},"source":"Crossref","is-referenced-by-count":7,"title":["Advances in the management of complications from cirrhosis"],"prefix":"10.1093","volume":"12","author":[{"given":"Jasleen","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Surgery, David Geffen School of Medicine at UCLA , Los Angeles, CA, USA"},{"name":"Department of Medicine, David Geffen School of Medicine at UCLA , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ebaid","sequence":"additional","affiliation":[{"name":"Department of Surgery, David Geffen School of Medicine at UCLA , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[{"name":"Department of Surgery, David Geffen School of Medicine at UCLA , Los Angeles, CA, USA"},{"name":"Department of Medicine, David Geffen School of Medicine at UCLA , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"2024080516362711800_goae072-B1","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.3748\/wjg.v28.i41.5910","article-title":"Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions","volume":"28","author":"Liu","year":"2022","journal-title":"World J Gastroenterol"},{"key":"2024080516362711800_goae072-B2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis\u2014aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024080516362711800_goae072-B3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","article-title":"Pathophysiology of portal hypertension","volume":"18","author":"Iwakiri","year":"2014","journal-title":"Clin Liver Dis"},{"key":"2024080516362711800_goae072-B4","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1007\/978-3-642-37078-6_144","article-title":"Pathophysiology of portal hypertension","volume":"23","author":"Morales-Ruiz","year":"2015","journal-title":"PanVasc Med"},{"key":"2024080516362711800_goae072-B5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014Renewing consensus in portal hypertension","volume":"76","author":"De Franchis","year":"2021","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3350\/cmh.2014.20.1.6","article-title":"Hepatic venous pressure gradient: clinical use in chronic liver disease","volume":"20","author":"Suk","year":"2014","journal-title":"Clin Mol Hepatol"},{"key":"2024080516362711800_goae072-B7","doi-asserted-by":"crossref","first-page":"203794","DOI":"10.1155\/2012\/203794","article-title":"Clinical manifestations of portal hypertension","volume":"2012","author":"Al-Busafi","year":"2012","journal-title":"Int J Hepatol"},{"key":"2024080516362711800_goae072-B8","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","article-title":"AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis","volume":"79","author":"Kaplan","year":"2024","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B9","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/hep.28824","article-title":"Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the \u201cAnticipate\u201d study","volume":"64","author":"Abraldes","year":"2016","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"2024080516362711800_goae072-B11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.32737","article-title":"Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: a national cohort study","volume":"77","author":"Serper","year":"2023","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"Villanueva","year":"2022","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/liv.14040","article-title":"Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: a meta-analysis","volume":"39","author":"Wong","year":"2019","journal-title":"Liver Int"},{"key":"2024080516362711800_goae072-B14","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s10620-018-5092-6","article-title":"Nonselective beta-blockers do not affect survival in cirrhotic patients with ascites","volume":"63","author":"Facciorusso","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2024080516362711800_goae072-B15","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jhep.2020.05.011","article-title":"Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites","volume":"73","author":"T\u00e9llez","year":"2020","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B16","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.15439","article-title":"Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis","volume":"50","author":"Tergast","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2024080516362711800_goae072-B17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/HEP.0000000000000530","article-title":"AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B18","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/hep.30220","article-title":"Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis","volume":"69","author":"Sharma","year":"2019","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0034-1382794","article-title":"The history and future of transjugular intrahepatic portosystemic shunt: food for thought","volume":"31","author":"Saad","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"2024080516362711800_goae072-B20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1089\/lap.2017.0560","article-title":"Polytetrafluoroethylene-covered stent graft versus bare stent in transjugular intrahepatic portosystemic shunt: systematic review and meta-analysis","volume":"28","author":"Triantafyllou","year":"2018","journal-title":"J Laparoendosc Adv Surg Tech A"},{"key":"2024080516362711800_goae072-B21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00270-019-02162-4","article-title":"Clinical efficacy of transjugular intrahepatic portosystemic shunt created with expanded polytetrafluoroethylene-covered stent-grafts: 8-mm versus 10-mm","volume":"42","author":"Luo","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2024080516362711800_goae072-B22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2017.05.006","article-title":"Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding","volume":"67","author":"Wang","year":"2017","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B23","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1056\/NEJMoa0910102","article-title":"Early use of TIPS in patients with cirrhosis and variceal bleeding","volume":"362","author":"Garc\u00eda-Pag\u00e1n","year":"2010","journal-title":"N Engl J Med"},{"key":"2024080516362711800_goae072-B24","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jhep.2020.04.024","article-title":"Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS","volume":"73","author":"Trebicka","year":"2020","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/hep.30182","article-title":"Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study","volume":"69","author":"Hern\u00e1ndez-Gea","year":"2019","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.15797","article-title":"Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding","volume":"52","author":"Dunne","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2024080516362711800_goae072-B27","first-page":"CD010180","article-title":"Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension","volume":"2015","author":"R\u00edos Castellanos","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2024080516362711800_goae072-B28","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/hep.31718","article-title":"Endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration for prevention of gastric variceal bleeding: a randomized controlled trial","volume":"74","author":"Luo","year":"2021","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1440-1746.1996.tb00010.x","article-title":"Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration","volume":"11","author":"Kanagawa","year":"1996","journal-title":"J Gastroenterol Hepatol"},{"key":"2024080516362711800_goae072-B30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jgh.14463","article-title":"Recent development of balloon-occluded retrograde transvenous obliteration","volume":"34","author":"Kobayakawa","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"2024080516362711800_goae072-B31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1051-0443(07)61912-5","article-title":"Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy","volume":"12","author":"Fukuda","year":"2001","journal-title":"J Vasc Interv Radiol"},{"key":"2024080516362711800_goae072-B32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00270-009-9679-3","article-title":"Changes in portal systemic pressure gradient after balloon-occluded retrograde transvenous obliteration of gastric varices and aggravation of esophageal varices","volume":"32","author":"Tanihata","year":"2009","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2024080516362711800_goae072-B33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-0034-1382796","article-title":"Combining transjugular intrahepatic portosystemic shunt with balloon-occluded retrograde transvenous obliteration or augmenting TIPS with variceal embolization for the management of gastric varices: an evolving middle ground?","volume":"31","author":"Saad","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"2024080516362711800_goae072-B34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.05.042","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases","volume":"61","author":"American Association for the Study of Liver Diseases; European Association for the Study of the Liver","year":"2014","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B35","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"EASL Clinical Practice Guidelines on the management of hepatic encephalopathy","volume":"77","author":"European Association for the Study of the Liver","year":"2022","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/cld.445","article-title":"Pathophysiological mechanisms of hepatic encephalopathy","volume":"5","author":"Tranah","year":"2015","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2024080516362711800_goae072-B37","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4254\/wjh.v14.i4.670","article-title":"Evidence-based approach to management of hepatic encephalopathy in adults","volume":"14","author":"Hoilat","year":"2022","journal-title":"World J Hepatol"},{"key":"2024080516362711800_goae072-B38","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/hep.24423","article-title":"Characterization of fecal microbial communities in patients with liver cirrhosis","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B39","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B40","doi-asserted-by":"crossref","first-page":"G168","DOI":"10.1152\/ajpgi.00190.2011","article-title":"Linkage of gut microbiome with cognition in hepatic encephalopathy","volume":"302","author":"Bajaj","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2024080516362711800_goae072-B41","doi-asserted-by":"crossref","first-page":"100333","DOI":"10.1016\/j.aohep.2021.100333","article-title":"Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy","volume":"25","author":"Bloom","year":"2021","journal-title":"Ann Hepatol"},{"key":"2024080516362711800_goae072-B42","doi-asserted-by":"crossref","first-page":"26800","DOI":"10.1038\/srep26800","article-title":"Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis","volume":"6","author":"Ahluwalia","year":"2016","journal-title":"Sci Rep"},{"key":"2024080516362711800_goae072-B43","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jceh.2014.06.005","article-title":"Diagnosis of minimal hepatic encephalopathy","volume":"5","author":"Weissenborn","year":"2015","journal-title":"J Clin Exp Hepatol"},{"key":"2024080516362711800_goae072-B44","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJMra1600561","article-title":"Hepatic Encephalopathy","volume":"375","author":"Wijdicks","year":"2016","journal-title":"N Engl J Med"},{"key":"2024080516362711800_goae072-B45","first-page":"142","article-title":"Hepatic encephalopathy: an update on the pathophysiology and therapeutic options","volume":"5","author":"Elwir","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"2024080516362711800_goae072-B46","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"2024080516362711800_goae072-B47","first-page":"CD011585","article-title":"Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"7","author":"Zacharias","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2024080516362711800_goae072-B48","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/M20-0202","article-title":"The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial","volume":"174","author":"Bureau","year":"2021","journal-title":"Ann Intern Med"},{"key":"2024080516362711800_goae072-B49","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00253-021-11646-8","article-title":"Probiotics, prebiotics and synbiotics: safe options for next-generation therapeutics","volume":"106","author":"Yadav","year":"2022","journal-title":"Appl Microbiol Biotechnol"},{"key":"2024080516362711800_goae072-B50","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B51","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1053\/j.gastro.2019.01.033","article-title":"Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis","volume":"156","author":"Bajaj","year":"2019","journal-title":"Gastroenterology"},{"key":"2024080516362711800_goae072-B52","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/hep.21930","article-title":"Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis","volume":"46","author":"Hassanein","year":"2007","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B53","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/hep.26185","article-title":"Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial","volume":"57","author":"Ba\u00f1ares","year":"2013","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B54","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/lt.24440","article-title":"Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy","volume":"22","author":"Lynn","year":"2016","journal-title":"Liver Transpl"},{"key":"2024080516362711800_goae072-B55","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11901-019-00460-6","article-title":"The role of hepatic and splanchnic lymphatic system in portal hypertension and ascites","volume":"18","author":"Ribera","year":"2019","journal-title":"Curr Hepatology Rep"},{"key":"2024080516362711800_goae072-B57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-8278(03)00188-0","article-title":"Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety","volume":"39","author":"Santos","year":"2003","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14218\/JCTH.2019.00048","article-title":"Pathophysiology and prevention of paracentesis-induced circulatory dysfunction: a concise review","volume":"8","author":"Kulkarni","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"2024080516362711800_goae072-B59","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4254\/wjh.v13.i4.421","article-title":"Long-term albumin infusion in decompensated cirrhosis: A review of current literature","volume":"13","author":"Wong","year":"2021","journal-title":"World J Hepatol"},{"key":"2024080516362711800_goae072-B60","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"2024080516362711800_goae072-B61","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.13968","article-title":"Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites","volume":"39","author":"Di Pascoli","year":"2019","journal-title":"Liver Int"},{"key":"2024080516362711800_goae072-B62","first-page":"CD004889","article-title":"TIPS versus paracentesis for cirrhotic patients with refractory ascites","volume":"2006","author":"Saab","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2024080516362711800_goae072-B63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1478-3231.2005.01095.x","article-title":"Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis","volume":"25","author":"Deltenre","year":"2005","journal-title":"Liver Int"},{"key":"2024080516362711800_goae072-B64","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","article-title":"Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data","volume":"133","author":"Salerno","year":"2007","journal-title":"Gastroenterology"},{"key":"2024080516362711800_goae072-B65","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3748\/wjg.v20.i10.2704","article-title":"TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis","volume":"20","author":"Bai","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2024080516362711800_goae072-B66","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jhepr.2019.04.001","article-title":"Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival","volume":"1","author":"Piecha","year":"2019","journal-title":"JHEP Rep"},{"key":"2024080516362711800_goae072-B67","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.14309\/ajg.0000000000000959","article-title":"Sarcopenia Does Not Worsen Survival in Patients With Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites","volume":"115","author":"Benmassaoud","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2024080516362711800_goae072-B68","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jvir.2019.01.005","article-title":"Muscle gain after transjugular intrahepatic portosystemic shunt creation: time course and prognostic implications for survival in cirrhosis","volume":"30","author":"Jahangiri","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"2024080516362711800_goae072-B69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MEG.0b013e328359a759","article-title":"Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent","volume":"25","author":"Tsien","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2024080516362711800_goae072-B70","first-page":"51","article-title":"Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment","volume":"15","author":"C\u0103runtu","year":"2006","journal-title":"J Gastrointestin Liver Dis"},{"key":"2024080516362711800_goae072-B71","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep.1840120416","article-title":"Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial","volume":"12","author":"Gin\u00e9s","year":"1990","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B72","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2011.10.016","article-title":"Renal failure and cirrhosis: a systematic review of mortality and prognosis","volume":"56","author":"Fede","year":"2012","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B73","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"62","author":"Angeli","year":"2015","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-018-0022-7","article-title":"Hepatorenal syndrome","volume":"4","author":"Gin\u00e8s","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2024080516362711800_goae072-B75","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.3748\/wjg.v27.i26.3984","article-title":"Acute kidney injury and hepatorenal syndrome in cirrhosis","volume":"27","author":"Gupta","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2024080516362711800_goae072-B76","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archinte.1994.00420020117013","article-title":"Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis","volume":"154","author":"Caregaro","year":"1994","journal-title":"Arch Intern Med"},{"key":"2024080516362711800_goae072-B77","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1093\/ndt\/gfr354","article-title":"Pitfalls in assessing renal function in patients with cirrhosis\u2014potential inequity for access to treatment of hepatorenal failure and liver transplantation","volume":"26","author":"Davenport","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2024080516362711800_goae072-B78","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/liv.13600","article-title":"Cystatin C predicts acute kidney injury and mortality in cirrhotics: A prospective cohort study","volume":"38","author":"Maiwall","year":"2018","journal-title":"Liver Int"},{"key":"2024080516362711800_goae072-B79","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.29290","article-title":"Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis","volume":"66","author":"Markwardt","year":"2017","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B80","first-page":"e16084","article-title":"A review of hepatorenal syndrome","volume":"13","author":"Subedi","year":"2021","journal-title":"Cureus"},{"key":"2024080516362711800_goae072-B81","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B82","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh","year":"2012","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B83","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N Engl J Med"},{"key":"2024080516362711800_goae072-B84","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2024080516362711800_goae072-B85","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.32049","article-title":"Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the american association for the study of liver diseases","volume":"74","author":"Lai","year":"2021","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B86","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jhep.2018.05.025","article-title":"Karnofsky performance status before and after liver transplantation predicts graft and patient survival","volume":"69","author":"Thuluvath","year":"2018","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B87","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hep.28900","article-title":"A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis","volume":"65","author":"Tandon","year":"2017","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B88","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jhep.2020.03.029","article-title":"Changes in frailty are associated with waitlist mortality in patients with cirrhosis","volume":"73","author":"Lai","year":"2020","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B89","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1017\/S0007114520002366","article-title":"Royal Free Hospital-Nutritional Prioritizing Tool improves the prediction of malnutrition risk outcomes in liver cirrhosis patients compared with Nutritional Risk Screening 2002","volume":"124","author":"Wu","year":"2020","journal-title":"Br J Nutr"},{"key":"2024080516362711800_goae072-B90","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s10620-015-4015-z","article-title":"The royal free hospital-nutritional prioritizing tool is an independent predictor of deterioration of liver function and survival in cirrhosis","volume":"61","author":"Borhofen","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2024080516362711800_goae072-B91","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30828","article-title":"A North American expert opinion statement on sarcopenia in liver transplantation","volume":"70","author":"Carey","year":"2019","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B92","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ncp.10451","article-title":"Micronutrients in liver disease: roles, risk factors for deficiency, and recommendations for supplementation","volume":"35","author":"Kozeniecki","year":"2020","journal-title":"Nutr Clin Pract"},{"key":"2024080516362711800_goae072-B93","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/hep.32378","article-title":"AASLD practice guidance: palliative care and symptom-based management in decompensated cirrhosis","volume":"76","author":"Rogal","year":"2022","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B94","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/jgh.14877","article-title":"Early palliative care referral in patients with end stage liver disease is associated with reduced resource utilisation","volume":"35","author":"Barnes","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"2024080516362711800_goae072-B95","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jpainsymman.2019.07.011","article-title":"Outcomes of palliative care consultations for hospitalized patents with liver disease","volume":"58","author":"Ufere","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"2024080516362711800_goae072-B96","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jpainsymman.2019.06.023","article-title":"A pilot trial of an early palliative care intervention for patients with end-stage liver disease","volume":"58","author":"Shinall","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"2024080516362711800_goae072-B97","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.32723","article-title":"International trends in hepatocellular carcinoma incidence, 1978-2012","volume":"147","author":"Petrick","year":"2020","journal-title":"Int J Cancer"},{"key":"2024080516362711800_goae072-B98","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"2024080516362711800_goae072-B99","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cgh.2022.01.047","article-title":"The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): a Phase 3 Biomarker Study in the United States","volume":"21","author":"Tayob","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024080516362711800_goae072-B100","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2018181494","article-title":"Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"key":"2024080516362711800_goae072-B101","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"2024080516362711800_goae072-B102","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2024080516362711800_goae072-B103","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2024080516362711800_goae072-B104","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2024080516362711800_goae072-B105","doi-asserted-by":"crossref","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae072\/58736676\/goae072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae072\/58736676\/goae072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T17:34:08Z","timestamp":1722879248000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goae072\/7727525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":105,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goae072","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2023,12,22]]},"article-number":"goae072"}}